Anti-PRO846 antibodies

Details Anti-PRO846 antibodies Anti-PRO846 antibodies

2007-11-13

2007-11-13

Landsman, Robert S. (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387900, C530S388100, C530S388150

Reexamination Certificate

active

09978665

ABSTRACT:
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

REFERENCES:
Streichert LC, Birnbach CD, Reh TA., J Neurobiol. Jun. 15, 1999;39(4):475-90.
Petters RM et al., Nat Biotechnol. Oct. 1997;15(10):965-70.
Caminci P et al., Methods in Enzymology. 303:19-44, 1999.
Ripps H. “Cell Death in Retinitis Pigmentosa: Gap Juncitons and the ‘Bystander’ Effect” Exp. Eye Res., vol. 74 (2002), pp. 327-336.
Farrar G.J., et al. “On the genetics of retinitis pigmentosa and on mutation-independent therapeutic intervention” EMBO J., vol. 21, No. 5 (Mar. 1, 2002), pp. 857-864.
Jackson et al.,Eur. J. Immunol. 22(5):1157-1163 (1992).
Clark et al.,Exp. Hematol. 25(8):759 (1997).
Daish et al.,Immunol. 79(1):55-63 (1993).
Clark et al.,Tissue Antigens48:461 (1996).
Dayhoff, Accession No. P—AAB65300, WO 200073454-A1, Pub Date: Dec. 7, 2000, A. J. Ashkenazi et al.
Dayhoff, Accession No. P—AAB19580, WO 200053760-A2, Pub Date: Sep. 14, 2000, N. Ferrara et al.
Dayhoff, Accession No. P—AAB44273, WO 200053756-A2, Pub Date: Sep. 14, 2000, A. J. Ashkenazi et al.
Dayhoff, Accession No. P—AAY41717, WO 9946281-A2, Pub Date: Sep. 16, 1999, W. I. Wood et al.
Dayhoff, Accession No. P—AAB27653, WO 200053757-A2, Sep. 14, 2000, A. J. Ashkenazi et al.
GenBank, Accession No. P—AAF44269, WO 200073454-A1, Pub Date: Dec. 7, 2000, A. J. Ashkenazi et al.
GenBank, Accession No. P—AAA88517, WO 200053760-A2, Pub Date: Sep. 14, 2000, N. Ferrara et al.
Benjamin et al., “Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal”, Proc, Natl. Sci USA, vol. 94, pp. 8761-8766, Aug. 1997.
Bozyczko-Coyne et al., “A rapid fluorometric assay to measure neuronal survival in vitro”, Journal of Neuroscience Methods, vol. 50, pp. 205-216, 1993.
Fontaine et al., “Survival of Purified Rat Photoreceptors in Vitro Is Stimulated Directly by Fibrolast Growth Factor-2”, The Journal of Neuroscience, vol. 18, No. 23, pp. 9662-9672, Dec. 1, 1998.
Jiang et al., “Selenium-Induced Inhibition of Angiogenesis in Mammary Cancer at Chemopreventive Levels of Intake”, Molecular Carcinogenesis, vol. 26, pp. 213-225, 1999.
Levin et al., “Effect of Lipid Peroxidation Inhibition on Retinal Ganglion Cell Death”, Investigative Ophthalmology & Visual Science, vol. 37, No. 13, Dec. 1996.
Otori et al., “Neurotoxic Effects of Low Doses of Glutamate on Purified Rat Retinal Ganglion Cells”, Investigative Ophthalmology & Visual Science, vol. 39, No. 6, May 1998.
Otori et al., “Protective effect of nilvadipine against glutamate neurotoxicity in purified retinal ganglion cells”, Brain Research, vol. 961, pp. 213-219, 2003.

Affiliated with

Also associated with

Rating

Anti-PRO846 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-PRO846 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-PRO846 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3822798